CellWell record HH-407815
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors
Hans Gelderblom; Emanuela Palmerini; Michiel van de Sande; Javier Martin-Broto; Gabriel Tinoco; Elyse Seltzer; Madhu Davies; Ruth Coll; Sander Veltkamp; Jean-Yves Blay
2026
In plain language
This protocol describes a randomized, double-blind phase III trial comparing a short intravenous CSF-1R antibody with placebo in adults and adolescents with tenosynovial giant cell tumors not amenable to surgery.
- Evidence
- Established
- Design
- Randomized controlled trial
Cite this record: https://thecellwell.org/studies/HH-407815
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.